Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation

Background Loss of major histocompatibility complex class I (MHC-I) in tumor cells limits the use of immune checkpoint blockade (ICB) in colorectal cancer. Nevertheless, the regulatory mechanism of MHC-I downregulation in tumor cells has not been fully elucidated. Overexpression of CEMIP in tumor ti...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Zhu, Jiao Li, Tao Zhang, Lei Zhao, Min Jin, Jinghua Ren, Jing Tang, Haihong Wang, Zhenyu Lin, Qing Liang, Ruiqi Li, Biying Zhang, Qingling Hua, Guojie Xu, Jiayuan Chen, Lanqing Wang, Dejun Zhang, Dandan Yu
Format: Article
Language:English
Published: BMJ Publishing Group 2023-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/1/e005592.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832582710784163840
author Ying Zhu
Jiao Li
Tao Zhang
Lei Zhao
Min Jin
Jinghua Ren
Jing Tang
Haihong Wang
Zhenyu Lin
Qing Liang
Ruiqi Li
Biying Zhang
Qingling Hua
Guojie Xu
Jiayuan Chen
Lanqing Wang
Dejun Zhang
Dandan Yu
author_facet Ying Zhu
Jiao Li
Tao Zhang
Lei Zhao
Min Jin
Jinghua Ren
Jing Tang
Haihong Wang
Zhenyu Lin
Qing Liang
Ruiqi Li
Biying Zhang
Qingling Hua
Guojie Xu
Jiayuan Chen
Lanqing Wang
Dejun Zhang
Dandan Yu
author_sort Ying Zhu
collection DOAJ
description Background Loss of major histocompatibility complex class I (MHC-I) in tumor cells limits the use of immune checkpoint blockade (ICB) in colorectal cancer. Nevertheless, the regulatory mechanism of MHC-I downregulation in tumor cells has not been fully elucidated. Overexpression of CEMIP in tumor tissues is associated with a poor prognosis in colorectal cancer. Here, in this research, we aim to address the role of CEMIP in mediating MHC-I expression in tumor cells and investigate the underlying regulatory mechanisms.Method Protein levels were analyzed by western blotting. Flow cytometry analysis was used to examine immune cells. Protein–protein interactions were investigated by co-immunoprecipitation and proximity ligation assays. The intracellular trafficking of MHC-I was revealed by an immunofluorescent technique. In addition, the effect of CEMIP on tumor growth and the antitumor efficacy of targeting CEMIP in combination with ICB therapy were evaluated in murine models of colorectal cancer.Results We reported that CEMIP specifically downregulated the expression of MHC-I on the surface of murine and human colon cancer cells, hindering the cytotoxicity of CD8+ T cells. We also demonstrated that CEMIP restricted CD8+ T-cell antitumor activities both in vitro and in vivo due to impaired MHC-I-mediated antigen presentation. Correspondingly, the combination of CEMIP inhibition and ICB impeded tumor growth and enhanced therapeutic efficacy. Mechanistically, CEMIP acted as an adaptor for the interaction betweenMHC-I and clathrin, which drove MHC-I internalization via clathrin-dependent endocytosis. Furthermore, CEMIP anchored internalized MHC-I to lysosomes for degradation, disrupting the recycling of MHC-I to the cell surface.Conclusion Overall, our study unveils a novel regulatory mechanism of MHC-I on tumor cell surfaces by CEMIP-mediated internalization and degradation. Furthermore, targeting CEMIP provides an effective strategy for colorectal cancer immunotherapy.
format Article
id doaj-art-d793afab723a4d6eb2336efde66c10a4
institution Kabale University
issn 2051-1426
language English
publishDate 2023-01-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-d793afab723a4d6eb2336efde66c10a42025-01-29T11:55:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-01-0111110.1136/jitc-2022-005592Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradationYing Zhu0Jiao Li1Tao Zhang2Lei Zhao3Min Jin4Jinghua Ren5Jing Tang6Haihong Wang7Zhenyu Lin8Qing Liang9Ruiqi Li10Biying Zhang11Qingling Hua12Guojie Xu13Jiayuan Chen14Lanqing Wang15Dejun Zhang16Dandan Yu17Department of Laboratory, People’s Hospital of Yuxi City, Yuxi, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China3 Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China1Shandong Cancer Hospital Affiliated To Shandong First Medical University, Jinan, China1 Department of Pharmacy, Shanghai Fourth People`s Hospital Affiliated to Tongji University, Shanghai, Shanghai, ChinaInstitute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China1 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China1 Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaInstitute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Emergency, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBackground Loss of major histocompatibility complex class I (MHC-I) in tumor cells limits the use of immune checkpoint blockade (ICB) in colorectal cancer. Nevertheless, the regulatory mechanism of MHC-I downregulation in tumor cells has not been fully elucidated. Overexpression of CEMIP in tumor tissues is associated with a poor prognosis in colorectal cancer. Here, in this research, we aim to address the role of CEMIP in mediating MHC-I expression in tumor cells and investigate the underlying regulatory mechanisms.Method Protein levels were analyzed by western blotting. Flow cytometry analysis was used to examine immune cells. Protein–protein interactions were investigated by co-immunoprecipitation and proximity ligation assays. The intracellular trafficking of MHC-I was revealed by an immunofluorescent technique. In addition, the effect of CEMIP on tumor growth and the antitumor efficacy of targeting CEMIP in combination with ICB therapy were evaluated in murine models of colorectal cancer.Results We reported that CEMIP specifically downregulated the expression of MHC-I on the surface of murine and human colon cancer cells, hindering the cytotoxicity of CD8+ T cells. We also demonstrated that CEMIP restricted CD8+ T-cell antitumor activities both in vitro and in vivo due to impaired MHC-I-mediated antigen presentation. Correspondingly, the combination of CEMIP inhibition and ICB impeded tumor growth and enhanced therapeutic efficacy. Mechanistically, CEMIP acted as an adaptor for the interaction betweenMHC-I and clathrin, which drove MHC-I internalization via clathrin-dependent endocytosis. Furthermore, CEMIP anchored internalized MHC-I to lysosomes for degradation, disrupting the recycling of MHC-I to the cell surface.Conclusion Overall, our study unveils a novel regulatory mechanism of MHC-I on tumor cell surfaces by CEMIP-mediated internalization and degradation. Furthermore, targeting CEMIP provides an effective strategy for colorectal cancer immunotherapy.https://jitc.bmj.com/content/11/1/e005592.full
spellingShingle Ying Zhu
Jiao Li
Tao Zhang
Lei Zhao
Min Jin
Jinghua Ren
Jing Tang
Haihong Wang
Zhenyu Lin
Qing Liang
Ruiqi Li
Biying Zhang
Qingling Hua
Guojie Xu
Jiayuan Chen
Lanqing Wang
Dejun Zhang
Dandan Yu
Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
Journal for ImmunoTherapy of Cancer
title Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
title_full Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
title_fullStr Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
title_full_unstemmed Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
title_short Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
title_sort tumor cemip drives immune evasion of colorectal cancer via mhc i internalization and degradation
url https://jitc.bmj.com/content/11/1/e005592.full
work_keys_str_mv AT yingzhu tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT jiaoli tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT taozhang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT leizhao tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT minjin tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT jinghuaren tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT jingtang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT haihongwang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT zhenyulin tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT qingliang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT ruiqili tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT biyingzhang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT qinglinghua tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT guojiexu tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT jiayuanchen tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT lanqingwang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT dejunzhang tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation
AT dandanyu tumorcemipdrivesimmuneevasionofcolorectalcancerviamhciinternalizationanddegradation